



Collaborative Working Executive Summary

Published on www.bayer.co.uk

Project title	Building the future: West Somerset Community Macular Treatment Centre Joint Working Project
Project partners	Somerset NHS Foundation Trust Bayer plc
Project summary	Somerset NHS Foundation Trust and Bayer plc are working in partnership under a joint working agreement to create a macular treatment centre for patients in West Somerset. This will offer rapid access to treatment in a bespoke space designed to offer optimum patient flow and efficiency whilst delivering the required capacity. It is expected that overall experience of patients with macular conditions across West Somerset will improve by rapid access to the service in a location which has excellent public transport links and ample free parking for patients and staff.
Expected benefits to patients/patient care/NHS and Bayer	<p>Patients</p> <ul style="list-style-type: none"> • Intends to provide a suitable environment for the treatment of macular patients: <ul style="list-style-type: none"> ➢ Aims to increase the number of injection slots from baseline ➢ Intends to enable faster access to treatment for new patients from baseline measurements ➢ Aims to reduce waiting times for follow up treatment from baseline measurements ➢ Intends to reduce backlog from baseline measurements. <p>Somerset NHS FT</p> <ul style="list-style-type: none"> • Intends to improve productivity and efficiency through utilisation of available additional sessions from baseline measurements. • Aims to support compliance with NICE targets for both Age-Related Macular Degeneration and Diabetic Retinopathy and Retinal Vein Occlusion, by designing and implementing treatment pathways based on current NICE guidelines. • Intends to increase patient satisfaction and improve experience. <p>Bayer</p> <ul style="list-style-type: none"> • Demonstrating Bayer’s commitment to ophthalmology patient care by collaborating on a large strategic project. • Increasing injection capacity to support delivery of patient care in line with NICE guidelines (Bayer has a NICE approved treatment in this therapy area). • Opportunity to share learnings and best practice from this collaboration within the ophthalmology community to support service improvement in other locations.
Start date	May 2022

Date of Preparation: May 2022

Job bag number: RP-PF-OPHT-GB-0597